TimesSquare Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

TimesSquare Capital Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.2M	Sell	369,377 -19,213	-5%	-$1.23M	0.34%	97
2026 Q1	$27.3M	Buy	388,590 +56,144	+17%	+$3.92M	0.46%	82
2025 Q4	$27.2M	Buy	332,446 +64,941	+24%	+$4.85M	0.41%	96
2025 Q3	$15.9M	Buy	+267,505	New	+$13.2M	0.23%	132
2023 Q2	–	Sell	-1,192,660	Closed	-$15M	–	187
2023 Q1	$15M	Sell	1,192,660 -236,650	-17%	-$3.46M	0.22%	143
2022 Q4	$21M	Sell	1,429,310 -90,600	-6%	-$1.5M	0.3%	129
2022 Q3	$26M	Buy	1,519,910 +38,200	+3%	+$607K	0.36%	125
2022 Q2	$21.6M	Buy	1,481,710 +822,110	+125%	+$12.3M	0.3%	131
2022 Q1	$11.1M	Sell	659,600 -1,200	-0.2%	-$22.3K	0.12%	167
2021 Q4	$14.9M	Buy	660,800 +10,020	+2%	+$261K	0.13%	175
2021 Q3	$14M	Sell	650,780 -35,925	-5%	-$889K	0.12%	192
2021 Q2	$19.9M	Buy	686,705 +234,805	+52%	+$7.33M	0.16%	180
2021 Q1	$14.6M	Sell	451,900 -12,700	-3%	-$470K	0.12%	186
2020 Q4	$19.2M	Buy	+464,600	New	+$13.2M	0.16%	181

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TimesSquare Capital Management's TARS Position: Q2 2026 in Review

TimesSquare Capital Management reduced its Tarsus Pharmaceuticals (TARS) stake by 4.9% in Q2 2026, selling an estimated $1.23M and leaving 369,377 shares worth $23.2M. The position accounts for 0.34% of the portfolio, ranked #97.

TimesSquare Capital Management first reported a position in TARS in Q4 2020 and has held it in 14 quarters since. The position peaked at $27.3M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

TimesSquare Capital Management held 369,377 shares of Tarsus Pharmaceuticals worth $23.2M as of Q2 2026.
TimesSquare Capital Management sold 19,213 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.23M.
Tarsus Pharmaceuticals made up 0.34% of TimesSquare Capital Management's portfolio in Q2 2026, its #97 holding.
TimesSquare Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
TimesSquare Capital Management's Tarsus Pharmaceuticals position peaked at $27.3M in Q1 2026.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on TimesSquare Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.